Skip to content

Lung Cancer Health Center

Medical Reference Related to Lung Cancer

  1. Lung Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Changes to This Summary (03 / 01 / 2013)

    The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Description of the EvidenceUpdated statistics with estimated new cases and deaths for 2013 (cited American Cancer Society as reference 1).This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  2. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - nci_ncicdr0000062947-nci-header

    This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Small Cell Lung Cancer Treatment

  3. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Limited-Stage Small Cell Lung Cancer Treatment

    Standard Treatment Options for Patients With Limited-Stage Small Cell Lung Cancer (SCLC)Standard treatment options for patients with limited-stage SCLC include the following:Chemotherapy and radiation therapy.Combination chemotherapy alone.Surgery followed by chemotherapy or chemoradiotherapy.Prophylactic cranial irradiation.Chemotherapy and radiation therapyCombined-modality treatment with etoposide and cisplatin with thoracic radiation therapy (TRT) is the most widely used treatment for patients with limited-stage disease (LD) SCLC.Evidence (combined modality treatment):Survival. The following results have been reported in clinical trials:Mature results of prospective randomized trials suggest that combined-modality therapy produces a modest but significant improvement in survival of 5% at 3 years compared with chemotherapy alone.[1,2,3][Level of evidence: 1iiA]Clinical trials have consistently achieved median survivals of 18 to 24 months and 40% to 50% 2-year survival

  4. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Non-Small Cell Lung Cancer

    Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. The lungs are a pair of cone-shaped breathing organs in the chest. The lungs bring oxygen into the body as you breathe in. They release carbon dioxide,a waste product of the body’s cells,as you breathe out. Each lung has sections called lobes. The left lung has two lobes. The right ..

  5. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

  6. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stages IA and IB NSCLC Treatment

    Standard Treatment Options for Stages IA and IB NSCLCStandard treatment options for stage IA NSCLC and IB NSCLC include the following:Surgery.Radiation therapy.Chemotherapy and radiation therapy have not been shown to improve outcomes in stage I NSCLC that has been completely resected.SurgerySurgery is the treatment of choice for patients with stage I NSCLC. A lobectomy or segmental, wedge, or sleeve resection may be performed as appropriate. Patients with impaired pulmonary function are candidates for segmental or wedge resection of the primary tumor. Careful preoperative assessment of the patient's overall medical condition, especially the patient's pulmonary reserve, is critical in considering the benefits of surgery. The immediate postoperative mortality rate is age related, but a 3% to 5% mortality rate with lobectomy can be expected.[1]Evidence (surgery):The Lung Cancer Study Group conducted a randomized study (LCSG-821) that compared lobectomy

  7. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Treatment Options for Recurrent Non-Small Cell Lung Cancer

    Treatment of recurrent non-small cell lung cancer may include the following:External radiation therapy as palliative therapy, to relieve pain and other symptoms and improve the quality of life.Chemotherapy.Targeted therapy with a tyrosine kinase inhibitor.Laser therapy or internal radiation therapy using an endoscope.Radiosurgery (for certain patients who cannot have surgery).Surgery to remove a very small amount of cancer that has spread to the brain.Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with recurrent non-small cell lung cancer. For more specific results, refine the search by using other search features, such as the location of the trial, the type of treatment, or the name of the drug. General information about clinical trials is available from the NCI Web site.

  8. Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV NSCLC Treatment

    Forty percent of patients with newly diagnosed non-small cell lung cancer (NSCLC) have stage IV disease. Treatment goals are to prolong survival and control disease-related symptoms. Treatment options include cytotoxic chemotherapy and targeted agents. Factors influencing treatment selection include comorbidity, performance status (PS), histology, and molecular genetic features of the cancer. Radiation therapy and surgery are generally used in selective cases for symptom palliation.Standard Treatment Options for Stage IV NSCLCStandard treatment options for stage IV NSCLC include the following:Cytotoxic combination chemotherapy (first line) with platinum (cisplatin or carboplatin) and paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan, and pemetrexed. Factors influencing treatment.Histology.Age versus comorbidity.PS.Combination chemotherapy with

  9. Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI

    Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

  10. Lung Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - About This PDQ Summary

    About PDQPhysician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government's center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.Purpose of This SummaryThis PDQ cancer information summary has current

Displaying 41 - 50 of 208 Articles << Prev Page 1 2 3 4 5 6 7 8 9 10 Next >>

Today on WebMD

Broken cigarette
Do you know the myths from the facts?
man with a doctor
Our health check will steer you in the right direction.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Lung cancer xray
See it in pictures, plus read the facts.
 
15 Cancer Symptoms Men Ignore
FEATURE
Lung Cancer Risks Myths and Facts
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
Improving Lung Cancer Survival Targeted Therapy
VIDEO
 
Lung Cancer Surprising Differences Between Sexes
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Lung Cancer Surgery Options
VIDEO
 

WebMD Special Sections